Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611163 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
A Phase 3 study of Moderate to Severe Genital Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
- Active
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT06611163 is a Phase 3 study of Moderate to Severe Genital Psoriasis that is active but no longer recruiting, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 206 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT06611163, a Phase 3 study of Moderate to Severe Genital Psoriasis, is active but no longer recruiting, sponsored by Sun Pharmaceutical Industries Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tildrakizumab 100 mg
Study Locations (20)
California
- Smary Cures Clinical Research - Anaheim
- California Dermatology & Clinical Research Institute - Encinitas
- T. Joseph Raoof MD, Inc./Encino Research Center - Encino
- Center for Dermatology Clinical Research, Inc - Fremont
- Dermatology Research Associates - Los Angeles
- LA Universal Research Center Inc, Suite 1 - Los Angeles
- Amicis Research Center - Northridge
- Therapeutics Clinical Research - San Diego
- Dermatology Institute and Skin Care Center, Inc. DBA Clinical Science Institute - Santa Monica
Florida
- Coral Gables Dermatology & Aesthetics - Coral Gables
- Florida Academic Centers Research and Education, LLC - Coral Gables
- Homestead Associates in Research Inc - Homestead
- Genomics Medical Research - Miami
- Med-Care Research - Miami
Georgia
- Dermatology Affiliates Research Institute, LLC - Atlanta
- Mcintosh Clinic, PC - Thomasville
Michigan
- Oakland Hills Dermatology PC - Auburn Hills
- The Derm Institute of West Michigan - Caledonia
Colorado
- Paradigm Clinical Research - Wheat Ridge
Indiana
- The Indiana Clinical Trials Center - Plainfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06611163
The ClinicalTrials.gov registry entry for NCT06611163 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Genital Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06611163 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06611163 about?
NCT06611163 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.". Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
What is the current status of trial NCT06611163?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2025-03-21. Estimated completion is 2027-02.
What conditions does trial NCT06611163 study?
This clinical trial studies the following conditions: Moderate to Severe Genital Psoriasis.
What interventions are being tested in trial NCT06611163?
The interventions under investigation include: Placebo (DRUG), Tildrakizumab 100 mg (DRUG).
Who is sponsoring clinical trial NCT06611163?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06611163 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.